Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK studying if best-selling shingles vaccine lowers dementia risk
04:28am, Tuesday, 25'th Mar 2025
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of dementia.
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to
April 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GSK
05:30pm, Monday, 24'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
NEW YORK CITY, NY / ACCESS Newswire / March 24, 2025 / WHY: New York, N.Y., March 24, 2025.
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
03:40pm, Monday, 24'th Mar 2025
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
Class Action Filed Against GSK plc (GSK) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
02:30pm, Monday, 24'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK Lawsuit – GSK
02:26pm, Monday, 24'th Mar 2025
NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.
NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between Febr
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to
Shareholders that Lost Money on GSK plc (GSK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
10:30am, Monday, 24'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline - GSK
07:25am, Monday, 24'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
NEW YORK CITY, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK p
Class Action Filed Against GSK plc (GSK) - April 7, 2025 Deadline to Join - Contact The Gross Law Firm
05:45am, Monday, 24'th Mar 2025
NEW YORK , March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period list
GSK says European regulator reviewing expanded use of asthma drug Nucala
03:26am, Monday, 24'th Mar 2025
GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's asthama drug Nucala as an additional treatment for chronic obstructive pulmonary
Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact Levi & Korsinsky
12:17pm, Sunday, 23'rd Mar 2025
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
